Anesthesiology and Pain Medicine

Published by: Kowsar

Acute Severe Thrombocytopenia Occurring After Administration of Eptifibatide Postpones Emergent Coronary Artery Surgery

Brent T. Boettcher 1 , Timothy J. Olund 1 and Paul S. Pagel 2 , *
Authors Information
1 Departments of Anesthesiology, the Medical College of Wisconsin, Milwaukee, Wisconsin, USA
2 The Anesthesia Service, the Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin, USA
Article information
  • Anesthesiology and Pain Medicine: August 01, 2016, 6 (4); e37575
  • Published Online: June 21, 2016
  • Article Type: Case Report
  • Received: March 3, 2016
  • Revised: May 2, 2016
  • Accepted: May 29, 2016
  • DOI: 10.5812/aapm.37575

To Cite: Boettcher B T, Olund T J, Pagel P S. Acute Severe Thrombocytopenia Occurring After Administration of Eptifibatide Postpones Emergent Coronary Artery Surgery, Anesth Pain Med. 2016 ; 6(4):e37575. doi: 10.5812/aapm.37575.

Abstract
Copyright © 2016, Iranian Society of Regional Anesthesia and Pain Medicine (ISRAPM). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
Footnote
References
  • 1. Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood. 2002; 100(6): 2071-6[PubMed]
  • 2. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med. 1998; 339(7): 436-43[DOI][PubMed]
  • 3. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997; 349(9063): 1422-8[PubMed]
  • 4. Esprit Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy . Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000; 356(9247): 2037-44[DOI][PubMed]
  • 5. Hongo RH, Brent BN. Association of eptifibatide and acute profound thrombocytopenia. Am J Cardiol. 2001; 88(4): 428-31[PubMed]
  • 6. Tanaka KA, Vega JD, Kelly AB, Hanson SR, Levy JH. Eptifibatide-induced thrombocytopenia and coronary bypass operation. J Thromb Haemost. 2003; 1(2): 392-4[PubMed]
  • 7. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007; 357(6): 580-7[DOI][PubMed]
  • 8. Sane DC, Damaraju LV, Topol EJ, Cabot CF, Mascelli MA, Harrington RA, et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol. 2000; 36(1): 75-83[PubMed]
  • 9. Russell KN, Schnabel JG, Rochetto RP, Tanner MC. Acute profound thrombocytopenia associated with readministration of eptifibatide: case report and review of the literature. Pharmacotherapy. 2009; 29(7): 867-74[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments